Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting (Q44700478)

5 December 2017

Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting (English)

1 reference

5 December 2017

1 reference

Bin Wu

1

1 reference

5 December 2017

Li Kun

series ordinal

2

1 reference

5 December 2017

Xiaoyan Liu

series ordinal

3

1 reference

5 December 2017

Ben He

series ordinal

4

1 reference

5 December 2017

language of work or name

1 reference

1 February 2014

1 reference

Cardiovascular Drugs and Therapy

5 December 2017

1 reference

5 December 2017

28

1 reference

5 December 2017

1

1 reference

5 December 2017

87-98

1 reference

Atrial fibrillation: current knowledge and future directions in epidemiology and genomics

5 December 2017

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Lifetime risk for development of atrial fibrillation: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Epidemiology, risk factors for stroke, and management of atrial fibrillation in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The fiamingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Effect of home testing of international normalized ratio on clinical events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Pharmacogenetics of warfarin: current status and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Meta-analysis of rivaroxaban and bleeding risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Modelling in the economic evaluation of health care: selecting the appropriate approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Validation of Clinical Classification Schemes for Predicting Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Atrial fibrillation and stroke prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Canadian atrial fibrillation anticoaguiation (CAFA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Risk factors for intracerebral hemorrhage in the general population: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Bayesian calibration of a natural history model with application to a population model for colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

National patterns of risk-standardized mortality and readmission for acute myocardial infarction and heart failure. Update on publicly reported outcomes measures based on the 2010 release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Development of WHO guidelines on generalized cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10557-013-6490-9

10.1007/S10557-013-6490-9

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference